Objective:To investigate the survival outcomes and prognostic factors in patients undergoing radical resection for pancreatic body and tail cancer.Methods:A retrospective case series study was conducted on 992 patients who underwent radical resection for pancreatic body and tail cancer at the Pancreatic Center of the First Affiliated Hospital of Nanjing Medical University from January 2016 to June 2024. In this study, 577 (58.2%) were male and 415 (41.8%) were female,with an age of (65±9) years (range: 26 to 86 years). Follow-up continued until June 2024. Survival rates were estimated using the Kaplan-Meier method,and prognostic factors were identified using univariate and multivariate Cox proportional hazards models.Results:Among 992 patients,open surgery was the predominant approach (89.1%, 884/992), and radical antegrade modular pancreatosplenectomy (RAMPS) was performed in 317 patients (32.0%). Combined organ resection,venous resection,and arterial resection were performed in 23.5%, 9.3%,and 11.2% of patients,respectively. The rates of R0, R1-1 mm, and R1-direct resections were 49.8% (494/992),41.5% (412/992), and 8.7% (86/992),respectively. Stage ⅡB was the most common TNM stage (32.2%,319/992). A total of 801 patients (80.8%) received adjuvant chemotherapy. The median follow-up period was 32.0(8.8) months(range:3.2 to 105.3 months),during which 508 patients (51.2%) died. The overall median survival (OS) was 26.4 months,with 1-,3-, and 5-year survival rates of 79.0%,40.0%, and 29.0%, respectively. In the recent five years (from 2020 to 2024), the median OS improved significantly to 34.1 months compared to 20.0 months from 2016 to 2019 ( P<0.01). Histological subtype analysis showed that the median OS time was 26.7 months for pancreatic ductal adenocarcinoma (PDAC, n=855),58.9 months for invasive intraductal papillary mucinous carcinoma (IPMC, n=32),and 15.7 months for adenosquamous carcinoma of pancreas (ASCP, n=73) ( P=0.001). Among PDAC patients, adjuvant chemotherapy significantly improved survival (29.1 months vs. 14.4 months, P<0.01);in IPMC patients, adjuvant chemotherapy also extended survival (65.7 months vs. 58.9 months, P=0.047). Although ASCP patients receiving chemotherapy had a longer median OS time than those without (18.8 months vs. 8.9 months),the difference was not statistically significant ( P=0.151). Multivariate Cox regression analysis in PDAC patients indicated that adjuvant chemotherapy, R0 resection, T stage,N stage,and tumor differentiation were independent prognostic factors ( P<0.01). The median OS time by TNM stage was:not reached for stage ⅠA, 51.6 months for ⅠB, 25.5 months for ⅡA, 23.7 months for ⅡB, 23.0 months for Ⅲ, and 14.4 months for Ⅳ. The median OS time for R0,R1-1 mm,and R1-direct resections was 34.1,24.7,and 15.7 months,respectively ( P<0.01). Conclusion:Adjuvant chemotherapy,R0 resection,tumor stage,and differentiation are independent prognostic factors for pancreatic body and tail cancer.

Objective:To investigate the survival outcomes and prognostic factors in patients undergoing radical resection for pancreatic body and tail cancer.Methods:A retrospective case series study was conducted on 992 patients who underwent radical resection for pancreatic body and tail cancer at the Pancreatic Center of the First Affiliated Hospital of Nanjing Medical University from January 2016 to June 2024. In this study, 577 (58.2%) were male and 415 (41.8%) were female,with an age of (65±9) years (range: 26 to 86 years). Follow-up continued until June 2024. Survival rates were estimated using the Kaplan-Meier method,and prognostic factors were identified using univariate and multivariate Cox proportional hazards models.Results:Among 992 patients,open surgery was the predominant approach (89.1%, 884/992), and radical antegrade modular pancreatosplenectomy (RAMPS) was performed in 317 patients (32.0%). Combined organ resection,venous resection,and arterial resection were performed in 23.5%, 9.3%,and 11.2% of patients,respectively. The rates of R0, R1-1 mm, and R1-direct resections were 49.8% (494/992),41.5% (412/992), and 8.7% (86/992),respectively. Stage ⅡB was the most common TNM stage (32.2%,319/992). A total of 801 patients (80.8%) received adjuvant chemotherapy. The median follow-up period was 32.0(8.8) months(range:3.2 to 105.3 months),during which 508 patients (51.2%) died. The overall median survival (OS) was 26.4 months,with 1-,3-, and 5-year survival rates of 79.0%,40.0%, and 29.0%, respectively. In the recent five years (from 2020 to 2024), the median OS improved significantly to 34.1 months compared to 20.0 months from 2016 to 2019 ( P<0.01). Histological subtype analysis showed that the median OS time was 26.7 months for pancreatic ductal adenocarcinoma (PDAC, n=855),58.9 months for invasive intraductal papillary mucinous carcinoma (IPMC, n=32),and 15.7 months for adenosquamous carcinoma of pancreas (ASCP, n=73) ( P=0.001). Among PDAC patients, adjuvant chemotherapy significantly improved survival (29.1 months vs. 14.4 months, P<0.01);in IPMC patients, adjuvant chemotherapy also extended survival (65.7 months vs. 58.9 months, P=0.047). Although ASCP patients receiving chemotherapy had a longer median OS time than those without (18.8 months vs. 8.9 months),the difference was not statistically significant ( P=0.151). Multivariate Cox regression analysis in PDAC patients indicated that adjuvant chemotherapy, R0 resection, T stage,N stage,and tumor differentiation were independent prognostic factors ( P<0.01). The median OS time by TNM stage was:not reached for stage ⅠA, 51.6 months for ⅠB, 25.5 months for ⅡA, 23.7 months for ⅡB, 23.0 months for Ⅲ, and 14.4 months for Ⅳ. The median OS time for R0,R1-1 mm,and R1-direct resections was 34.1,24.7,and 15.7 months,respectively ( P<0.01). Conclusion:Adjuvant chemotherapy,R0 resection,tumor stage,and differentiation are independent prognostic factors for pancreatic body and tail cancer.

Objective To investigate the expression and clinical significance of heat shock protein family A member 5(HSPA5)and apolipoprotein B mRNA editing enzyme catalytic polypeptide-like protein 3B(APO-BEC3B)in high-risk human papillomavirus(HR-HPV)positive cervical cancer patients.Methods A total of 86 patients with HR-HPV positive cervical cancer tissues diagnosed and treated in Zhuhai Integrated Tradi-tional Chinese and Western Medicine Hospital from March 2019 to March 2021 were retrospectively collected as the case group,50 cases of HR-HPV negative cervical cancer patients tissues diagnosed and treated during the same period were selected as the case control group,and 50 cases of normal cervical tissues from patients undergoing total hysterectomy were selected as the benign control group during the same period.The protein expressions of HSPA5 and APOBEC3B were analyzed by immunohistochemistry.The expressions of HSPA5 mRNA and APOBEC3B mRNA were detected by real-time fluorescence quantitative PCR.Kaplan-Meier sur-vival curve was used for survival analysis,and Cox proportional hazards regression model was used to analyze the prognostic factors of HR-HPV positive cervical cancer patients.Results The expressions of HSPA5 mR-NA and APOBEC3B mRNA in the case group were higher than that in the case control group and benign con-trol group,and the difference was statistically significant(P＜0.05).The positive expressions of HSPA5 pro-tein and APOBEC3B protein in the case group were higher than those in the case control group and the benign control group,and the difference was statistically significant(P＜0.05).Compared with FIGO stage Ⅰ A-Ⅰ B and without lymph node metastasis,the positive rates of HSPA5 and APOBEC3B proteins in HR-HPV positive cancer tissues with FIGO stage Ⅱ A and lymph node metastasis were higher,and the difference was statistically significant(P＜0.05).The 3-year survival rate of HSPA5 protein positive group was 68.52％(37/54),which was lower than that of HSPA5 protein negative group(87.50％,28/32),and the difference was statistically significant(Log Rank x2=4.103,P=0.043).The 3-year survival rate of APOBEC3B protein positive group was 67.31％(35/52),which was lower than that of APOBEC3B protein negative group(88.24％,30/34),and the difference was statistically significant(Log Rank x2=5.241,P=0.022).FIGO stage(HR=1.570,95％CI:1.038-2.374),lymph node metastasis(HR=1.754,95％CI:1.109-2.775)and HSPA5 protein(HR=1.616,95％CI:1.154-2.265)and APOBEC3B protein(HR=1.449,95％CI:1.095-1.918)in cancer tissues were independent factors affecting the prognosis of HR-HPV positive cervical cancer(P＜0.05).Conclusion HSPA5 and APOBEC3B mRNA and protein levels are significantly increased in HR-HPV positive cervical cancer.The protein expression of HSPA5 and APOBEC3B is related to the pro-gression and prognosis of patients with HR-HPV positive cervical cancer,which is a new prognostic marker for evaluating the prognosis of HR-HPV positive cervical cancer.

Background: s/Aims: Distal pancreatectomy with splenectomy (DPS) is a common surgical procedure for pancreatic body cancer.However, spleen-preserving distal pancreatectomy (SPDP) utilizing the Warshaw technique (WT) in malignancies is generally not favored due to concerns about inadequate resection. This study aims to assess the feasibility and oncologic outcomes of employing SPDP with WT in pancreatic body cancer. Methods: We conducted a retrospective analysis comparing 21 SPDP patients with 63 DPS patients matched by propensity score from January 2018 to November 2022. Clinical outcomes and follow-up data were analyzed using R. Results: Both groups exhibited similar demographic, intraoperative, and pathological characteristics, with the exception of a reduced number of total lymph nodes (p = 0.006) in the SPDP group. There were no significant differences in the rates of postoperative complications, recurrence, or metastasis. Local recurrence predominantly occurred in the central region as opposed to the spleen region.There were no cases of isolated recurrences in the splenic region. Median overall survival and recurrence-free survival times were 51.5 months for SPDP vs 30.5 months for DPS and 18.7 months vs 16.8 months, respectively (p > 0.05). The incidence of partial splenic infarction and left-side portal hypertension in the SPDP group was 28.6% (6/21) and 9.5% (2/21), respectively, without necessitating splenic abscess puncture, splenectomy, or causing bleeding from perigastric varices. Conclusions SPDP did not negatively impact local recurrence or survival rates in selected pancreatic body cancer patients. Further studies are necessary for validation.

Background: s/Aims: Distal pancreatectomy with splenectomy (DPS) is a common surgical procedure for pancreatic body cancer.However, spleen-preserving distal pancreatectomy (SPDP) utilizing the Warshaw technique (WT) in malignancies is generally not favored due to concerns about inadequate resection. This study aims to assess the feasibility and oncologic outcomes of employing SPDP with WT in pancreatic body cancer. Methods: We conducted a retrospective analysis comparing 21 SPDP patients with 63 DPS patients matched by propensity score from January 2018 to November 2022. Clinical outcomes and follow-up data were analyzed using R. Results: Both groups exhibited similar demographic, intraoperative, and pathological characteristics, with the exception of a reduced number of total lymph nodes (p = 0.006) in the SPDP group. There were no significant differences in the rates of postoperative complications, recurrence, or metastasis. Local recurrence predominantly occurred in the central region as opposed to the spleen region.There were no cases of isolated recurrences in the splenic region. Median overall survival and recurrence-free survival times were 51.5 months for SPDP vs 30.5 months for DPS and 18.7 months vs 16.8 months, respectively (p > 0.05). The incidence of partial splenic infarction and left-side portal hypertension in the SPDP group was 28.6% (6/21) and 9.5% (2/21), respectively, without necessitating splenic abscess puncture, splenectomy, or causing bleeding from perigastric varices. Conclusions SPDP did not negatively impact local recurrence or survival rates in selected pancreatic body cancer patients. Further studies are necessary for validation.

Background: s/Aims: Distal pancreatectomy with splenectomy (DPS) is a common surgical procedure for pancreatic body cancer.However, spleen-preserving distal pancreatectomy (SPDP) utilizing the Warshaw technique (WT) in malignancies is generally not favored due to concerns about inadequate resection. This study aims to assess the feasibility and oncologic outcomes of employing SPDP with WT in pancreatic body cancer. Methods: We conducted a retrospective analysis comparing 21 SPDP patients with 63 DPS patients matched by propensity score from January 2018 to November 2022. Clinical outcomes and follow-up data were analyzed using R. Results: Both groups exhibited similar demographic, intraoperative, and pathological characteristics, with the exception of a reduced number of total lymph nodes (p = 0.006) in the SPDP group. There were no significant differences in the rates of postoperative complications, recurrence, or metastasis. Local recurrence predominantly occurred in the central region as opposed to the spleen region.There were no cases of isolated recurrences in the splenic region. Median overall survival and recurrence-free survival times were 51.5 months for SPDP vs 30.5 months for DPS and 18.7 months vs 16.8 months, respectively (p > 0.05). The incidence of partial splenic infarction and left-side portal hypertension in the SPDP group was 28.6% (6/21) and 9.5% (2/21), respectively, without necessitating splenic abscess puncture, splenectomy, or causing bleeding from perigastric varices. Conclusions SPDP did not negatively impact local recurrence or survival rates in selected pancreatic body cancer patients. Further studies are necessary for validation.

Addressing the core issues of conventional ward models with"building+informatization module",which included system isolation,severely medical and nursing burdens,and poorly patients'experience,this research focused on how to construct autonomous ward space system based on industrialized manufacturing,embodied Artificial Intelligence(AI),and a Cloud-Edge-End architecture through technological integration and paradigm innovation.Combined with advancements of industry 4.0 and AI technique,it firstly proposed an evolutionary path with six-stages from Engineering → Assembly → Industrialization →Productization → Equipped → Embodied Intelligent Entity.It clearly defined the"Ward Space Intelligent Entity"as a standardized medical equipment entity that integrated industrialized manufacturing,integrated architectural space,and embodied intelligence.The study constructed a"Cloud-Edge-End"collaborative architecture that used edge computing as its core,which can explain its offline autonomous characteristics.It explored implementation pathways including"Platform+Module"manufacturing,menu-style customization,on-site assembly,and digital operation and maintenance.The research also analyzed challenges such as interdisciplinary integration and standards/regulations,and proposed solution approach.This study expanded the architectural-scale application of embodied intelligence theory,which provided actionable technical plans and building references for building smart hospital,the industrialized transformation of intelligent medical spaces,and the upgrading of the industry of medical equipment.

To establish a rapid Akabane virus(AKAV)antibody detection method in animals,the re-combination AKAV N protein was expressed by the expression system of Escherichia coli,puri-fied from the supernatant,and used to immunized New Zealand White rabbits.The polyclonal anti-body against AKAV N protein had a titer of 1∶8.192×107 and showed good reactivity.After opti-mizing the reaction conditions,an AKAV double antigen sandwich ELISA antibody detection method was established.This method can detect AKAV antibody in a variety of animals including cattles,sheep and goats.The method had no cross-reactivity with the positive serum of BTV,EHDV,BEV and PRV with the intra-and inter-batch coefficients of variation less than 10％.Com-pared with the AKAV blocking ELISA kit,the sensibility of the method was increased by 8-16 folds with a compliance rate of 93.33％and the κ value of 0.864.These results showed that the double antigen sandwich ELISA displayed strong specificity,high sensitivity and repeatability,which could provide technical suport for detection,the prevention and control of AKAV.

To establish a rapid Akabane virus(AKAV)antibody detection method in animals,the re-combination AKAV N protein was expressed by the expression system of Escherichia coli,puri-fied from the supernatant,and used to immunized New Zealand White rabbits.The polyclonal anti-body against AKAV N protein had a titer of 1∶8.192×107 and showed good reactivity.After opti-mizing the reaction conditions,an AKAV double antigen sandwich ELISA antibody detection method was established.This method can detect AKAV antibody in a variety of animals including cattles,sheep and goats.The method had no cross-reactivity with the positive serum of BTV,EHDV,BEV and PRV with the intra-and inter-batch coefficients of variation less than 10％.Com-pared with the AKAV blocking ELISA kit,the sensibility of the method was increased by 8-16 folds with a compliance rate of 93.33％and the κ value of 0.864.These results showed that the double antigen sandwich ELISA displayed strong specificity,high sensitivity and repeatability,which could provide technical suport for detection,the prevention and control of AKAV.

Addressing the core issues of conventional ward models with"building+informatization module",which included system isolation,severely medical and nursing burdens,and poorly patients'experience,this research focused on how to construct autonomous ward space system based on industrialized manufacturing,embodied Artificial Intelligence(AI),and a Cloud-Edge-End architecture through technological integration and paradigm innovation.Combined with advancements of industry 4.0 and AI technique,it firstly proposed an evolutionary path with six-stages from Engineering → Assembly → Industrialization →Productization → Equipped → Embodied Intelligent Entity.It clearly defined the"Ward Space Intelligent Entity"as a standardized medical equipment entity that integrated industrialized manufacturing,integrated architectural space,and embodied intelligence.The study constructed a"Cloud-Edge-End"collaborative architecture that used edge computing as its core,which can explain its offline autonomous characteristics.It explored implementation pathways including"Platform+Module"manufacturing,menu-style customization,on-site assembly,and digital operation and maintenance.The research also analyzed challenges such as interdisciplinary integration and standards/regulations,and proposed solution approach.This study expanded the architectural-scale application of embodied intelligence theory,which provided actionable technical plans and building references for building smart hospital,the industrialized transformation of intelligent medical spaces,and the upgrading of the industry of medical equipment.